Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Cervical Carcinoma clinical trials
Every US clinical trial registered for Recurrent Cervical Carcinoma — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
10 US clinical trials · 2 currently recruiting
The research picture
Recurrent Cervical Carcinoma has 10 registered US clinical trials, 2 of them open to new participants right now — about 20% of the total.
- 2
- recruiting participants now
- 20%
- of trials open to enrollment
- 0
- in Phase 3–4 (later-stage)
- 4
- top sponsor: National Cancer Institute (NCI)
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Precigen
NCT06157151
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
NCT03968406
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Meghan Shea
NCT06238635
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
NCT02257528
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
Mayo Clinic
NCT04574635
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
Gynecologic Oncology Group
NCT00309959
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
National Cancer Institute (NCI)
NCT00057863
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
Gynecologic Oncology Group
NCT01267253
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
National Cancer Institute (NCI)
NCT01266447
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
NCT02921269
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Recurrent Cervical Carcinoma Trial Landscape
ClinicalTrials.gov lists 10 US studies indexed under Recurrent Cervical Carcinoma, and 2 of those are currently open to recruitment — roughly 20% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Recurrent Cervical Carcinoma shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 9 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Recurrent Cervical Carcinoma is led by National Cancer Institute (NCI) with 4 indexed trials, alongside 5 other organizations in the top contributor list. The list on this page surfaces up to 10 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Recurrent Cervical Carcinoma?
PlainTrial tracks 10 US clinical trials for Recurrent Cervical Carcinoma, of which 2 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Recurrent Cervical Carcinoma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.